Welcome to our dedicated page for Allogene Therapeutics SEC filings (Ticker: ALLO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Allogene Therapeutics, Inc. (Nasdaq: ALLO) SEC filings page on Stock Titan provides access to the company’s regulatory documents as filed with the U.S. Securities and Exchange Commission. As a Nasdaq-listed clinical-stage biotechnology company, Allogene files periodic reports and current reports that describe its AlloCAR T pipeline, financial condition, and key risks.
Among the most relevant filings for ALLO are its annual reports on Form 10-K and quarterly reports on Form 10-Q, which discuss clinical programs such as cemacabtagene ansegedleucel (cema-cel) in large B-cell lymphoma, ALLO-329 in autoimmune disease, and ALLO-316 in renal cell carcinoma. These reports also include detailed risk factor sections covering topics like gene-editing technology, reliance on licensed TALEN-based platforms, and intellectual property disputes referenced in company disclosures.
Allogene also submits numerous current reports on Form 8-K to describe material events. Recent 8-K filings have furnished quarterly financial results, outlined changes to the ALPHA3 trial’s lymphodepletion regimen following safety review, and described third-party patent litigation involving Cellectis’s TALEN technology on which Allogene relies. Other filings document matters such as annual meeting voting results and the continued listing of ALLO common stock on The Nasdaq Stock Market LLC.
On Stock Titan, investors can use AI-powered tools to review these filings, surface key points, and understand how disclosures about clinical trial design, safety findings, intellectual property, and governance may relate to ALLO stock. The filings page is a central resource for tracking Allogene’s regulatory history, financial reporting, and formal statements about its allogeneic CAR T development strategy.
Allogene Therapeutics, Inc. files its annual report as a clinical-stage company focused on off‑the‑shelf, allogeneic CAR T therapies for cancer and autoimmune disease. Its approach uses gene‑edited donor T cells and a proprietary Dagger® technology to improve persistence and limit rejection.
The company’s strategy centers on three core programs: cema‑cel for large B‑cell lymphoma in the pivotal Phase 2 ALPHA3 first‑line consolidation trial, ALLO‑316 for renal cell carcinoma with RMAT designation, and ALLO‑329 for systemic autoimmune diseases with multiple Fast Track designations. Interim ALPHA3 MRD data are planned for April 2026 and initial ALLO‑329 proof‑of‑concept data for June 2026. Allogene highlights substantial accumulated and expected future losses, heavy dependence on a few lead assets and partners, manufacturing and regulatory complexity, and significant competition from autologous CAR T and other novel therapies.
Allogene Therapeutics reported fourth quarter and full-year 2025 results and highlighted progress across its allogeneic CAR T pipeline. The pivotal Phase 2 ALPHA3 trial of cema-cel in large B-cell lymphoma is underway, with an interim futility analysis focused on MRD clearance and early safety planned for April 2026.
The Phase 1 RESOLUTION trial of ALLO-329 in autoimmune disease is enrolling, with proof-of-concept data expected in June 2026. The company ended Q4 2025 with $258.3 million in cash, cash equivalents and investments, guiding that its cash runway extends into the first quarter of 2028. Full-year 2025 net loss was $190.9 million, or $0.87 per share.
Allogene Therapeutics, Inc. senior vice president and chief technical officer Benjamin Machinas Beneski reported a mandatory sale of common stock to cover taxes on vested restricted stock units. He sold 7,132 shares in a sell-to-cover transaction at a weighted average price of $2.60 per share, with individual sale prices ranging from $2.60 to $2.67. After this tax-related sale, he directly owned 203,040 shares of Allogene common stock. The filing notes this transaction was required under the company’s equity incentive plan and did not represent a discretionary trade by the executive.
Allogene Therapeutics, Inc. reported a Form 144 notice for 7,132 shares of Common Stock tied to the vesting of a restricted stock unit award on
Allogene Therapeutics, Inc. shareholder Arie Belldegrun reports beneficial ownership of 13,248,170 shares of common stock, equal to 5.8% of the company as of December 31, 2025. This total includes 3,885,280 shares issuable within 60 days upon exercise of stock options.
The filing aggregates shares held directly and through Bellco Legacy LLC, Bellco Legacy IV LLC, Vida Ventures LLC, Vida Ventures III, L.P., and Vida Ventures III-A, L.P. Ownership percentages are calculated using 224,730,144 Allogene shares outstanding as of November 4, 2025.
Pfizer Inc. reports beneficial ownership of 22,032,040 shares of Allogene Therapeutics, Inc. common stock, representing 9.0% of the class. This percentage is based on 224,730,144 shares outstanding as of November 4, 2025, as reported in Allogene’s Form 10-Q. The lower ownership percentage in this amendment results solely from Allogene issuing more shares, not from Pfizer selling or buying stock. Pfizer and its listed executives report no transactions in Allogene shares during the prior 60 days.
Allogene Therapeutics, Inc. shareholder David D. Chang reports beneficial ownership of 12,101,223 shares of common stock, representing 5.2% of the company. This percentage is based on 224,730,144 shares outstanding as of
Dr. Chang’s reported holdings include 6,373,347 shares issuable within 60 days of
Allogene Therapeutics SVP and Chief Technical Officer Benjamin Machinas Beneski reported new equity awards and a small share sale. On February 2, 2026, he sold 7,549 shares of common stock at a weighted average price of $1.73 solely to cover tax withholding on vesting restricted stock units, under a mandatory “sell to cover” arrangement rather than a discretionary trade. He received a stock option for 373,757 shares at $1.87 per share, vesting 25% on February 2, 2027 and the balance in 36 monthly installments. He was also granted 105,720 restricted stock units, each representing one share, vesting in four equal annual installments starting February 2, 2026, subject to continued service. Following these transactions, he directly owned 210,172 shares of common stock.
Allogene Therapeutics President and CEO David D. Chang reported new equity awards and a tax-related share sale. On February 2, 2026, he received a stock option for 1,387,931 shares of common stock at an exercise price of $1.87 per share, vesting 25% on February 2, 2027, with the rest vesting in 36 equal monthly installments. He also received 392,586 restricted stock units, each representing one share of common stock, vesting in four equal annual installments from February 2, 2026, subject to continued service. To cover tax withholding on RSU vesting, 95,269 shares of common stock were sold at a weighted average price of $1.80 in a mandated "sell to cover" transaction, which the filing states was not a discretionary trade. After these transactions, he directly beneficially owned 5,185,862 shares of common stock and additional indirect holdings through several family trusts.
Allogene Therapeutics’ chief financial officer Geoffrey M. Parker reported routine equity compensation activity and a tax-related share sale. On February 2, 2026, he sold 24,001 shares of common stock at a weighted average price of